Metagenomi Showcases Advanced AI-Enhanced Gene Editing for Neurological Disorders at ASGCT Meeting

Metagenomi Inc. (NASDAQ:MGX) is one of the best young stocks to buy and hold for 5 years. In mid-May, Metagenomi announced the presentation of 3 abstracts at the American Society of Gene & Cell Therapy/ASGCT 28th Annual Meeting, which was held from May 13 to 17 in New Orleans, Louisiana.

The presented data highlighted Metagenomi’s advancements in compact nucleases for extrahepatic gene editing and CRISPR-associated transposases/CAST for site-specific integration of large therapeutic genes. These advancements underscore the platform’s potential to develop next-gen, in vivo precision medicines, particularly for neurological disorders and diseases caused by loss-of-function mutations.

Metagenomi Showcases Advanced AI-Enhanced Gene Editing for Neurological Disorders at ASGCT Meeting.

A scientist in a laboratory holding a test tube filled with a glowing blue solution, representing the company’s nano-biopharmaceutical research and development.

Metagenomi’s proprietary gene editing toolbox is enhanced by AI and ML and has analyzed over 7.4 billion proteins and holds the potential to target any type of genetic mutation across the entire human genome. The company’s platform offers a full spectrum of gene editing technologies, which include ultra-small nucleases, base editors, and large gene integrations using CAST and RNA-Mediated Integration Systems/RIGS.

Metagenomi Inc. (NASDAQ:MGX) is a genetic medicines company that develops therapeutics for patients using a metagenomics-derived genome editing toolbox in the US.

While we acknowledge the potential of MGX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than MGX and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.